在体内 T 细胞耗竭的减低强度异基因干细胞移植后，具有高供体源性 T 细胞计数的患者有良好的结局。
Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.
机构信息
Bone Marrow Transplant Program, Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23298-0157, USA.
出版信息
Biol Blood Marrow Transplant. 2012 May;18(5):794-804. doi: 10.1016/j.bbmt.2011.10.011. Epub 2011 Oct 17.
Abstract
Patients with hematologic malignancies were conditioned using a rabbit antithymocyte globulin-based reduced-intensity conditioning regimen for allogeneic stem cell transplantation. Donor-derived CD3(+) cell count (ddCD3), a product of CD3(+) cell chimerism and absolute CD3(+) cell count, when <110/μL at 8 weeks post-stem cell transplantation predicted a high risk of sustained mixed chimerism and relapse. Alternatively, patients with a higher ddCD3 developed graft-versus-host disease more frequently, and when partially chimeric, had higher rates of conversion to full donor chimerism after withdrawal of immunosuppression. Early data from our small cohort of patients indicate that ddCD3 at 8 weeks may be used to guide decisions regarding withdrawal of immunosuppression and administration of donor lymphocyte infusion in partially T cell-depleted reduced-intensity regimens.
摘要
患者患有血液系统恶性肿瘤，接受了基于兔抗胸腺细胞球蛋白的减低强度预处理方案，进行异基因造血干细胞移植。供体来源的 CD3(+)细胞计数（ddCD3）是 CD3(+)细胞嵌合体和绝对 CD3(+)细胞计数的产物，在干细胞移植后 8 周时 <110/μL 预示着持续混合嵌合体和复发的高风险。相反，ddCD3 较高的患者更频繁地发生移植物抗宿主病，当部分嵌合时，在停止免疫抑制后，向完全供体嵌合的转化率更高。我们的小患者队列的早期数据表明，8 周时的 ddCD3 可用于指导决定是否停止免疫抑制以及输注供者淋巴细胞，用于部分 T 细胞耗竭的减低强度方案。
相似文献
1
Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.
Biol Blood Marrow Transplant. 2012 May;18(5):794-804. doi: 10.1016/j.bbmt.2011.10.011. Epub 2011 Oct 17.
2
Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Biol Blood Marrow Transplant. 2015 Jan;21(1):180-4. doi: 10.1016/j.bbmt.2014.08.018. Epub 2014 Aug 28.
3
4
Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Leukemia. 2002 Jan;16(1):13-21. doi: 10.1038/sj.leu.2402343.
5
Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.
Biol Blood Marrow Transplant. 2013 Jun;19(6):949-57. doi: 10.1016/j.bbmt.2013.03.001. Epub 2013 Mar 21.
6
Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Biol Blood Marrow Transplant. 2003 May;9(5):320-9. doi: 10.1016/s1083-8791(03)00077-6.
7
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880.
8
Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.
Biol Blood Marrow Transplant. 2014 Oct;20(10):1516-21. doi: 10.1016/j.bbmt.2014.05.025. Epub 2014 Jun 4.
9
Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.
Exp Hematol. 2003 Oct;31(10):865-72. doi: 10.1016/s0301-472x(03)00200-5.
10
Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
Am J Hematol. 2012 Dec;87(12):1074-8. doi: 10.1002/ajh.23319. Epub 2012 Aug 22.
引用本文的文献
1
Allogeneic haematopoietic cell transplants as dynamical systems: influence of early-term immune milieu on long-term T-cell recovery.
Clin Transl Immunology. 2023 Jul 13;12(7):e1458. doi: 10.1002/cti2.1458. eCollection 2023.
2
On the organization of human T-cell receptor loci: log-periodic distribution of T-cell receptor gene segments.
J R Soc Interface. 2016 Jan;13(114):20150911. doi: 10.1098/rsif.2015.0911.
3
Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.
Biol Blood Marrow Transplant. 2015 Jul;21(7):1237-45. doi: 10.1016/j.bbmt.2015.03.011. Epub 2015 Apr 4.
4
Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?
Front Immunol. 2014 Dec 3;5:613. doi: 10.3389/fimmu.2014.00613. eCollection 2014.
5
In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation.
Front Immunol. 2014 Nov 6;5:529. doi: 10.3389/fimmu.2014.00529. eCollection 2014.
6
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.
Exp Hematol. 2013 Sep;41(9):772-8. doi: 10.1016/j.exphem.2013.04.015. Epub 2013 May 18.
本文引用的文献
1
Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.
Bone Marrow Transplant. 2012 Dec;47(12):1513-9. doi: 10.1038/bmt.2012.81. Epub 2012 May 14.
2
A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
Eur J Haematol. 2011 Jan;86(1):57-66. doi: 10.1111/j.1600-0609.2010.01537.x. Epub 2010 Nov 25.
3
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.
Haematologica. 2010 Jun;95(6):989-95. doi: 10.3324/haematol.2009.013920. Epub 2009 Nov 30.
4
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
Leuk Lymphoma. 2009 Nov;50(11):1809-17. doi: 10.3109/10428190903200790.
5
Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation.
Bone Marrow Transplant. 2010 Apr;45(4):668-74. doi: 10.1038/bmt.2009.212. Epub 2009 Aug 17.
6
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants.
Biol Blood Marrow Transplant. 2009 Jul;15(7):856-63. doi: 10.1016/j.bbmt.2009.03.018.
7
Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
Br J Haematol. 2009 Mar;144(6):933-45. doi: 10.1111/j.1365-2141.2008.07533.x. Epub 2009 Jan 9.
8
Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.
Biol Blood Marrow Transplant. 2008 Oct;14(10):1148-1155. doi: 10.1016/j.bbmt.2008.07.013.
9
Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT.
Bone Marrow Transplant. 2008 Dec;42(11):723-31. doi: 10.1038/bmt.2008.244. Epub 2008 Aug 18.
10
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
Bone Marrow Transplant. 2008 Nov;42(9):569-79. doi: 10.1038/bmt.2008.259. Epub 2008 Aug 18.
Zotero 插件